87 related articles for article (PubMed ID: 15537833)
41. Genotype Analysis of
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; Chairez Hernández I; Córdova Hurtado LP; Loera Castañeda V; Patrón Romero L; Venzor Sánchez C; Payan Gándara H; Arechiga Gurrola D; Almanza Reyes H
Front Pharmacol; 2020; 11():616630. PubMed ID: 33613283
[No Abstract] [Full Text] [Related]
42. Carbonyl Reductase 3 (CBR3) Mediates 9-cis-Retinoic Acid-Induced Cytostatis and is a Potential Prognostic Marker for Oral Malignancy.
Ohkura-Hada S; Kondoh N; Hada A; Arai M; Yamazaki Y; Shindoh M; Kitagawa Y; Takahashi M; Ando T; Sato Y; Yamamoto M
Open Dent J; 2008; 2():78-88. PubMed ID: 19088887
[TBL] [Abstract][Full Text] [Related]
43. Bromoform activation. TiCl4-Mg-promoted CHBr2- and CBr3- transfer to a variety of aldehydes and ketones.
Yan TH; Chang SH; Chang CT; Lin CK; Liu CY
Org Lett; 2013 Nov; 15(22):5802-5. PubMed ID: 24191725
[TBL] [Abstract][Full Text] [Related]
44. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
45. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
46. Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli.
Malátková P; Ebert B; Wsól V; Maser E
Biochem Biophys Res Commun; 2012 Apr; 420(2):368-73. PubMed ID: 22425771
[TBL] [Abstract][Full Text] [Related]
47. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS; Karkling MJ; Lubieniecka JM; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Mar; 332(3):755-63. PubMed ID: 20007405
[TBL] [Abstract][Full Text] [Related]
48. Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES; Niesen FH; Lee WH; El-Hawari Y; Dunford JE; Kochan G; Wsol V; Martin HJ; Maser E; Oppermann U
PLoS One; 2009 Oct; 4(10):e7113. PubMed ID: 19841672
[TBL] [Abstract][Full Text] [Related]
49. Genes of Predisposition to Childhood Beta-Cell Acute Lymphoblastic Leukemia in the Kazakh Population.
Svyatova G; Boranbayeva R; Berezina G; Manzhuova L; Murtazaliyeva A
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2653-2666. PubMed ID: 37642051
[TBL] [Abstract][Full Text] [Related]
50. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á; Labrador J; Zubiaur P; Alcaraz R; Herrero MJ; Montesinos P; Abad-Santos F; Saiz-Rodríguez M
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335935
[TBL] [Abstract][Full Text] [Related]
51. Inter-Individual Variation and Cardioprotection in Anthracycline-Induced Heart Failure.
Norton N; Weil RM; Advani PP
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575190
[TBL] [Abstract][Full Text] [Related]
52. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Magdy T; Burridge PW
Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
[TBL] [Abstract][Full Text] [Related]
53. Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.
Yang X; Li G; Yang T; Guan M; An N; Yang F; Dai Q; Zhong C; Luo C; Gao Y; Das S; Xing Y; Shang H
Oxid Med Cell Longev; 2020; 2020():4894625. PubMed ID: 33110473
[TBL] [Abstract][Full Text] [Related]
54. Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report.
Singh P; Wang X; Hageman L; Chen Y; Magdy T; Landier W; Ginsberg JP; Neglia JP; Sklar CA; Castellino SM; Dreyer ZE; Hudson MM; Robison LL; Blanco JG; Relling MV; Burridge P; Bhatia S
Cancer; 2020 Sep; 126(17):4051-4058. PubMed ID: 32413235
[TBL] [Abstract][Full Text] [Related]
55. Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Hoefer CC; Blair RH; Blanco JG
J Pharm Sci; 2016 Jun; 105(6):2005-2008. PubMed ID: 27112290
[TBL] [Abstract][Full Text] [Related]
56. The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer.
Chen L; Yang J; Zheng M; Kong X; Huang T; Cai YD
PLoS One; 2015; 10(6):e0128696. PubMed ID: 26047514
[TBL] [Abstract][Full Text] [Related]
57. Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.
Bernstein D; Burridge P
Prog Pediatr Cardiol; 2014 Dec; 37(1-2):23-27. PubMed ID: 25530693
[No Abstract] [Full Text] [Related]
58. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
59. MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024.
Kalabus JL; Cheng Q; Blanco JG
PLoS One; 2012; 7(11):e48622. PubMed ID: 23133646
[TBL] [Abstract][Full Text] [Related]
60. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
